Compare UMC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | ILMN |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 18.9B |
| IPO Year | 2000 | 2000 |
| Metric | UMC | ILMN |
|---|---|---|
| Price | $8.00 | $128.90 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 15 |
| Target Price | N/A | ★ $114.93 |
| AVG Volume (30 Days) | ★ 8.2M | 1.5M |
| Earning Date | 01-20-2026 | 10-30-2025 |
| Dividend Yield | ★ 4.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.10 | ★ 4.46 |
| Revenue | ★ $7,746,022,974.00 | $4,288,000,000.00 |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $6.45 | $2.08 |
| P/E Ratio | ★ $14.89 | $28.91 |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $5.61 | $68.70 |
| 52 Week High | $8.33 | $153.06 |
| Indicator | UMC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 66.70 |
| Support Level | $7.15 | $124.27 |
| Resistance Level | $7.45 | $129.72 |
| Average True Range (ATR) | 0.17 | 3.90 |
| MACD | 0.08 | -0.41 |
| Stochastic Oscillator | 94.04 | 77.82 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.